OneMedNet Corp
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
ONMD$5.82-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| For the year ended December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(10,129) | $(33,780) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 57 | 28 | ||
| Stock-based compensation expense | 628 | 1,475 | ||
| Stock warrant expense | 35 | 9,207 | ||
| Change in fair value of warrant liabilities | (9) | (129) | ||
| Change in fair value of PIPE Notes | 97 | 269 | ||
| Change in fair value of Yorkville Note | 711 | - | ||
| Change in fair value of convertible promissory notes | - | 17,517 | ||
| Change in fair value of crypto assets – Bitcoin | (798) | - | ||
| Change in fair value of derivative liability | 434 | - | ||
| Realized gain on sale of crypto assets – Bitcoin | (120) | - | ||
| Non-cash SEPA commitment fee | 500 | - | ||
| Gain on forgiveness of CEBA loan | (15) | - | ||
| Non-cash interest | 121 | 11 | ||
| Change in operating assets and liabilities: | ||||
| Accounts receivable | (61) | (133) | ||
| Prepaid expenses and other current assets | (234) | (43) | ||
| Accounts payable & accrued expenses | 1,493 | 717 | ||
| Deferred revenues | 307 | 70 | ||
| Net cash used in operating activities | (6,983) | (4,791) | ||
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (51) | (44) | ||
| Purchases of crypto assets – Bitcoin | (2,900) | - | ||
| Proceeds from sales of crypto assets – Bitcoin | 969 | - | ||
| Net cash used in investing activities | (1,982) | (44) | ||
| Cash flows from financing activities: | ||||
| Proceeds from private placements, net of issuance costs | 6,270 | - | ||
| Proceeds from issuance of shareholder loans | 2,000 | 454 | ||
| Proceeds from issuance of Yorkville Note, net of issuance costs | 1,350 | - | ||
| Proceeds from line of credit borrowings | 500 | - | ||
| Repayment of CEBA loan | (30) | - | ||
| Repayment of deferred underwriter fees | (100) | - | ||
| Repayment for common stock repurchase | (200) | - | ||
| Repayment of shareholder loan | (200) | - | ||
| Repayment of line of credit borrowings | (500) | - | ||
| Proceeds from issuance of PIPE Notes | - | 1,500 | ||
| Proceeds from issuance of convertible notes | - | 4,175 | ||
| Proceeds from issuance of Series A-2 preferred stock | - | 16 | ||
| Business Combination costs | - | (1,534) | ||
| Net cash provided by financing activities | 9,090 | 4,611 | ||
| Net increase (decrease) in cash and cash equivalents | 125 | (224) | ||
| Cash and cash equivalents at beginning year | 47 | 271 | ||
| Cash and cash equivalents at end of year | $172 | $47 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $26 | $ | - | |
| Cash paid for taxes | $18 | $ | - | |
| Supplemental disclosures of non-cash investing and financing activities: | ||||
| Common shares issued to settle deferred underwriter fees | $242 | $ | - | |
| Recognition of prepaid forward contract in exchange for partial conversion of Yorkville Note | $343 | $ | - | |
| Common stock repurchase consideration in accounts payable and accrued expenses | $329 | $ | - | |
| Extinguishment of officer accrued salaries reclassified to additional paid-in capital | $132 | $ | - | |
| Insurance premium settled by issuance of note payable | $318 | $ | - | |
| Common shares issued to preferred shareholders | $ | - | $17,659 | |
| Common shares related to convertible promissory notes | $ | - | $47,935 | |
| Common shares issued to Data Knights shareholders | $ | - | $11,937 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.